SCHEMBL29397222

SCHEMBL29397222

CCCCCCCCCCCCCCCCc1cc(C(C)(C)C)ccc1S(=O)(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 1/20 0.44
HDAC3 O15379 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC2 Q92769 1/20 0.43
TRPV1 Q8NER1 1/20 0.41
STS P08842 2/20 0.41
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
MAPT P10636 3/20 0.40
HTT P42858 3/20 0.40
TSHR P16473 2/20 0.40
TP53 P04637 1/20 0.40
CYP3A4 P08684 1/20 0.40
ALOX5 P09917 1/20 0.40
TYR P14679 1/20 0.40
ALOX15 P16050 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
ALDH1A1 P00352 3/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KDM4E B2RXH2 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7787192 0.82 S1PR3 (0.47) MEN1KMT2AMAPTHTTTSHR
SCHEMBL8953038 0.82 MEN1 (0.43) MEN1KMT2AMAPTHTTTSHR
SCHEMBL7779141 0.82 S1PR3 (0.47) MEN1KMT2AMAPTHTTTSHR
SCHEMBL7779134 0.82 S1PR3 (0.47) MEN1KMT2AMAPTHTTTSHR
SCHEMBL8954900 0.82 S1PR3 (0.47) MEN1KMT2AMAPTHTTTSHR
SCHEMBL7787208 0.82 S1PR3 (0.47) MEN1KMT2AMAPTHTTTSHR
SCHEMBL339909 0.82 S1PR3 (0.47) MEN1KMT2AMAPTHTTTSHR
SCHEMBL16563961 0.82 S1PR3 (0.47) MEN1KMT2AMAPTHTTTSHR
SCHEMBL7787174 0.82 S1PR3 (0.47) MEN1KMT2AMAPTHTTTSHR
SCHEMBL11148043 0.82 MEN1 (0.46) GHSRTRPV1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230081679-A1 SURFACTANT VESICLES FOR VACCINE FORMULATION, TARGETED DRUG DELIVERY, AND TRANSFECTION UNIV MARYLAND (US) 2023-03-16 US claimed
US-20260001783-A1 ENHANCED FOAM REMOVAL OF TOTAL SUSPENDED SOLIDS AND MULTIPLY CHARGED CATIONS FROM AQUEOUS OR AQUEOUS/OIL MIXED PHASE VIA INCREASED VISCOELASTICITY ECOLAB USA INC (US) 2026-01-01 US disclosed
US-12428318-B2 Enhanced foam removal of total suspended solids and multiply charged cations from aqueous or aqueous/oil mixed phase via increased viscoelasticity ECOLAB USA INC. (US) 2025-09-30 US disclosed
US-12291748-B2 Acridinium ester-containing compounds and methods of using the same for chemiluminescence-based one-color sequencing MGI HOLDINGS CO., LIMITED (CN) 2025-05-06 US disclosed
CN-119236105-A Multifunctional anti-tumor nano-drug delivery system based on copper death and preparation method and application thereof 中南大学 2025-01-03 CN disclosed
US-20240286929-A1 ENHANCED FOAM REMOVAL OF TOTAL SUSPENDED SOLIDS AND MULTIPLY CHARGED CATIONS FROM AQUEOUS OR AQUEOUS/OIL MIXED PHASE VIA INCREASED VISCOELASTICITY ECOLAB USA INC. 2024-08-29 US disclosed
US-11987505-B2 Enhanced foam removal of total suspended solids and multiply charged cations from aqueous or aqueous/oil mixed phase via increased viscoelasticity ECOLAB USA INC. (US) 2024-05-21 US disclosed
US-11929257-B2 Etching solution and method for aluminum nitride VERSUM MATERIALS US, LLC (US) 2024-03-12 US disclosed
CN-117618580-A Medicine-carrying mesoporous silica and preparation method thereof 东沃同泰(凤城)生物工程有限公司 2024-03-01 CN disclosed
CN-117380276-A Preparation method of functional covalent organic framework nanocomposite capable of removing active oxygen 南京大学 2024-01-12 CN disclosed
US-20230339781-A1 ENHANCED FOAM FRACTIONATION OF OIL PHASE FROM AQUEOUS/OIL MIXED PHASE VIA INCREASED VISCOELASTICITY ECOLAB USA INC. 2023-10-26 US disclosed
CN-116421618-B Preparation method of Se@NADH and application of Se@NADH in spinal cord injury treatment 暨南大学 2023-09-29 CN disclosed
CN-116712566-A Nanometer system for resisting coronavirus infection and preparation method and application thereof 中国科学院上海硅酸盐研究所 2023-09-08 CN disclosed
US-11718540-B2 Enhanced foam fractionation of oil phase from aqueous/oil mixed phase via increased viscoelasticity ECOLAB USA INC. (US) 2023-08-08 US disclosed
CN-116421618-A Preparation method of Se@NADH and application of Se@NADH in spinal cord injury treatment 暨南大学 2023-07-14 CN disclosed
US-20230081679-A1 SURFACTANT VESICLES FOR VACCINE FORMULATION, TARGETED DRUG DELIVERY, AND TRANSFECTION UNIV MARYLAND (US) 2023-03-16 US disclosed
US-20220367199-A1 ETCHING SOLUTION AND METHOD FOR ALUMINUM NITRIDE VERSUM MATERIALS US, LLC (US) 2022-11-17 US disclosed
EP-4010484-A1 ACRIDINIUM ESTER-CONTAINING COMPOUNDS AND METHODS OF USING THE SAME FOR CHEMILUMINESCENCE-BASED ONE-COLOR SEQUENCING BGI Shenzhen Co., Limited (CN) 2022-06-15 EP disclosed
CN-114245830-A Acridinium ester-containing compound and method for using same for chemiluminescence-based monochromatic sequencing 深圳华大基因科技有限公司 2022-03-25 CN disclosed
CN-112957345-B Light-operated drug release degradable temperature-sensitive mesoporous silicon nanoparticle system 济南国科医工科技发展有限公司 2022-03-08 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001783-A1 ENHANCED FOAM REMOVAL OF TOTAL SUSPENDED SOLIDS AND MULTIPLY CHARGED CATIONS FROM AQUEOUS OR AQUEOUS/OIL MIXED PHASE VIA INCREASED VISCOELASTICITY FLOT1, FLNA, MUC1 GHSR 3744/4885HDAC3 2553/4885HDAC1 1897/4885
US-12291748-B2 Acridinium ester-containing compounds and methods of using the same for chemiluminescence-based one-color sequencing ACR, CES2, PDE6C GHSR 1101/4885HDAC3 3592/4885HDAC1 4146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.